Kintor Pharmaceutical Limited (HKEX: 9939), a China-based clinical-stage biotechnology company, announced on Wednesday that it has dosed the first batch of subjects in its phase one clinical trial of GT20029 in China.
The phase I trial, a randomised, double-blind, placebo-controlled study, is intended to assess the safety, tolerability, and pharmacokinetics of the product (gel/tincture) subsequent to the topical single and multiple ascending dose administration in healthy patients.
According to Kintor Pharmaceutical, the product is the first topical Proteolysis Targeting Chimera compound globally to enter the clinical stage. It received approval from The China Center for Drug Evaluation (CDE) and the US Food and Drug Administration (FDA) for phase one clinical trial for treating androgenetic alopecia and acne in April 2021 and July 2021 separately.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients